- Eliem Therapeutics ELYM, a Phase 2a biotech developing therapies for neuronal excitability disorders, filed an IPO prospectus with the SEC to raise up to $80 million.
- Its two lead candidates are ETX-810 and ETX-155.
- ETX-810 is currently in two Phase IIa studies looking at diabetic peripheral neuropathic pain and lumbosacral radicular pain. Data readouts are expected for the first half of 2022.
- ETX-155 is a GABA-positive allosteric modulator, which the company is calling ETX-155.
- Researchers plan to take this program into two Phase IIa studies for major depressive disorder and hormone-related depressive disorders, as well as a Phase Ib trial for epilepsy. Data here are expected in the second half of 2022 and the first half of 2023, respectively.
- IPO Filing prospectus here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
